Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | -2.80% | -8.04% | -25.36% |
May. 09 | Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 06 | Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy | CI |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-25.36% | 206M | C | ||
+7.69% | 113B | B+ | ||
+10.67% | 106B | B+ | ||
+0.41% | 22.27B | B | ||
-11.94% | 22.22B | B+ | ||
-5.99% | 19.43B | A- | ||
-37.36% | 17.87B | A- | ||
-5.27% | 17.24B | B | ||
+6.67% | 14.29B | C+ | ||
+36.42% | 12.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BLUE Stock
- Ratings bluebird bio, Inc.